This course is free with an Unlimited CE upgrade!

Upgrade to Premium Unlimited CE and access premium courses over 1.5 contact hours for free.

Upgrade NowLoading..

Package Includes

PLEASE NOTE: Where a post-test is not required for course completion, you will be prompted to attest that you completed the course. Some courses contain interactive elements that must be completed to advance through the course. You must complete all courses in the package and the overall evaluation in order to obtain a certificate of completion. This package contains the following courses:

  • Pharmacology of Weight Loss - No Test (0.5 Contact Hour)

    Claire Hartman, Johnny J. Bethea; Course Expiration Date: 12/31/26

  • Opioids and Chronic Pain Management - No Test (2 Contact Hours)

    Cathryn Ayers, Daniel Migliaccio, Johnny J. Bethea; Course Expiration Date: 12/31/26

  • Common Medications in Critical Care: Part 2 - No Test (1 Contact Hour)

    Emily Allen, Hansel Fernandes; Course Expiration Date: 12/31/26

  • Pharmacology of Oncology - No Test (1 Contact Hour)

    Johnny Bethea II, Alia Lutz; Course Expiration Date: 12/31/26

  • The Benefits and Risks of Glucocorticoid Drugs (1 Contact Hour)

    Johnny Bethea II, Brandy Verton; Course Expiration Date: 12/31/27

  • Common Medications in Critical Care: Part 1 - No Test (1.5 Contact Hours)

    Derek Gyllenhammer, Emily Allen; Course Expiration Date: 12/31/26

  • Pharmacology of Asthma - No Test (1 Contact Hour)

    Nicole Strickland, Ashley M. Coffey, Johnny J. Bethea; Course Expiration Date: 12/31/26

  • Pharmacology of Drugs for Sexually Transmitted Infections: Syphilis and Gonorrhea - No Test (1 Contact Hour)

    Claire Hartman; Course Expiration Date: 12/31/26

  • Pharmacology of Drugs for Sexually Transmitted Infections: Chancroid, Trichomonas,Chlamydia-No Test (0.5 Contact Hour)

    Adam Root, Claire Hartman; Course Expiration Date: 12/31/26

  • Pharmacology of Gastroesophageal Reflux Disease - No Test (0.5 Contact Hour)

    Emily Allen, Johnny Bethea II; Course Expiration Date: 12/31/26

  • Opioid Prescribing, Chronic Pain, and Opioid Use Disorder - No Test (1 Contact Hour)

    Cathryn Ayers; Course Expiration Date: 12/31/25

  • Pharmacology of Antipsychotics - No Test (1 Contact Hour)

    Alia Lutz; Course Expiration Date: 12/31/26

  • Pharmacology of Antifungal and Antiviral Drugs - No Test (1.5 Contact Hours)

    Johnny Bethea II, Andrea Powell; Course Expiration Date: 12/31/26

  • Pharmacology of Inflammatory Bowel Disease - No Test (0.5 Contact Hour)

    Emily Allen, Derek J. Gyllenhammer; Course Expiration Date: 12/31/26

  • Pharmacological Management of Bipolar Disorder - No Test (1 Contact Hour)

    Derek Gyllenhammer, Alia Lutz; Course Expiration Date: 12/31/26

  • Pharmacology of Anxiety Disorders - No Test (1 Contact Hour)

    Claire Hartman, Derek Gyllenhammer; Course Expiration Date: 12/31/26

  • Treatments for Hypertension - No Test (1 Contact Hour)

    Alia Lutz, Adam Root; Course Expiration Date; 12/31/26

  • Pharmacological Treatment of Deep Vein Thrombosis - No Test (1 Contact Hour)

    Andrea Powell; Course Expiration Date: 12/31/26

  • Pharmacology of Non-opioid Analgesics - No Test (1 Contact Hour)

    Emily Allen, Johnny J. Bethea; Course Expiration Date: 12/31/26

  • Prescribing Practices for Controlled Substances (1 Contact Hour)

    Sooa Devereaux, Doug Raiff, Nicholas Bertoni; Course Expiration Date: 12/31/26

  • Pharmacology of Antidepressants - No Test (1 Contact Hour)

    Andrea Powell; Course Expiration Date: 12/31/26

  • Pharmacology of Antibiotics: Part 1 - No Test (1 Contact Hour)

    Nicole Strickland, Johnny Bethea II; Course Expiration Date: 12/31/26

  • Treatment of Hypertension: Diuretics and Alpha and Beta Blockers - No Test (1 Contact Hour)

    Johnny Bethea II, Alia Lutz; Course Expiration Date: 21/31/26

  • Pharmacology of Antibiotics: Part 2 - No Test (1 Contact Hour)

    Nicole Strickland, Derek J. Gyllenhammer; Course Expiration Date: 12/31/26

  • Pharmacology of Drugs for Sexually Transmitted Infections: HIV - No Test (1.25 Contact Hours)

    Claire Hartman; Course Expiration Date: 12/31/26

Accreditation Information

NURSES

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, Kansas State Board of Nursing, Kentucky Board of Nursing, Michigan Board of Nursing, Mississippi Board of Nursing, New Hampshire Board of Nursing, New Mexico Board Of Nursing, North Dakota Board of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Registered Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.